Nicotine and Parkinson’s disease; implications for therapy
Identifieur interne : 002247 ( Ncbi/Checkpoint ); précédent : 002246; suivant : 002248Nicotine and Parkinson’s disease; implications for therapy
Auteurs : Maryka Quik ; Kathryn O Eary ; Caroline M. TannerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Nicotine.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- Animals, Humans.
Abstract
Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson’s disease. Beneficial effects may be several-fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson’s disease. This reduced incidence of Parkinson’s disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson’s disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates L-dopa-induced dyskinesias, a debilitating side effect that develops in the majority of patients on L-dopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson’s disease therapy to reduce disease progression, improve symptoms and/or decrease L-dopa-induced dyskinesias.
Url:
DOI: 10.1002/mds.21900
PubMed: 18683238
PubMed Central: 4430096
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000202
- to stream Pmc, to step Curation: 000202
- to stream Pmc, to step Checkpoint: 000437
- to stream PubMed, to step Corpus: 002116
- to stream PubMed, to step Curation: 002116
- to stream PubMed, to step Checkpoint: 002185
- to stream Ncbi, to step Merge: 002247
- to stream Ncbi, to step Curation: 002247
Links to Exploration step
PMC:4430096Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nicotine and Parkinson’s disease; implications for therapy</title><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name></author><author><name sortKey="O Eary, Kathryn" sort="O Eary, Kathryn" uniqKey="O Eary K" first="Kathryn" last="O Eary">Kathryn O Eary</name></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18683238</idno><idno type="pmc">4430096</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430096</idno><idno type="RBID">PMC:4430096</idno><idno type="doi">10.1002/mds.21900</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000202</idno><idno type="wicri:Area/Pmc/Curation">000202</idno><idno type="wicri:Area/Pmc/Checkpoint">000437</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">002116</idno><idno type="wicri:Area/PubMed/Curation">002116</idno><idno type="wicri:Area/PubMed/Checkpoint">002185</idno><idno type="wicri:Area/Ncbi/Merge">002247</idno><idno type="wicri:Area/Ncbi/Curation">002247</idno><idno type="wicri:Area/Ncbi/Checkpoint">002247</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nicotine and Parkinson’s disease; implications for therapy</title><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name></author><author><name sortKey="O Eary, Kathryn" sort="O Eary, Kathryn" uniqKey="O Eary K" first="Kathryn" last="O Eary">Kathryn O Eary</name></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Humans</term><term>Nicotine (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Nicotine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Accumulating evidence suggests that nicotine, a drug that stimulates nicotinic acetylcholine receptors, may be of therapeutic value in Parkinson’s disease. Beneficial effects may be several-fold. One of these is a protective action against nigrostriatal damage. This possibility stems from the results of epidemiological studies that consistently demonstrate an inverse correlation between tobacco use and Parkinson’s disease. This reduced incidence of Parkinson’s disease has been attributed to the nicotine in tobacco products, at least in part, based on experimental work showing a protective effect of nicotine against toxic insults. Second, several studies suggest a symptomatic effect of nicotine in Parkinson’s disease, although effects are small and somewhat variable. Third, recent data in nonhuman primates show that nicotine attenuates L-dopa-induced dyskinesias, a debilitating side effect that develops in the majority of patients on L-dopa therapy. Collectively, these observations suggest that nicotine or CNS selective nicotinic receptor ligands hold promise for Parkinson’s disease therapy to reduce disease progression, improve symptoms and/or decrease L-dopa-induced dyskinesias.</p></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="O Eary, Kathryn" sort="O Eary, Kathryn" uniqKey="O Eary K" first="Kathryn" last="O Eary">Kathryn O Eary</name><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002247 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002247 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= PMC:4430096
|texte= Nicotine and Parkinson’s disease; implications for therapy
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:18683238" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |